Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial
Adriana Balduzzi(Azienda Ospedaliera San Gerardo), Marianne Ifversen(Copenhagen University Hospital), Stelios Graphakos(Boston Children's Hospital), Jean‐Hugues Dalle(Inserm), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Franco Locatelli(Bambino Gesù Children's Hospital), Peter Bader(Goethe University Frankfurt), Gergely Kriván(National Center for Epidemiology), Jochen Buechner(Oslo University Hospital), Francesca Limido(University of Milano-Bicocca), Birgit Burkhardt(University Hospital Münster), Roland Meisel(Düsseldorf University Hospital), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Jacek Wachowiak(Poznan University of Medical Sciences), Raquel Staciuk, Marc Bierings(University Medical Center Utrecht), Peter Švec(Comenius University Bratislava), Petr Sedláček(University Hospital in Motol), Tayfun Güngör, Akif Yeşilipek(Bahçeşehir University), Marc Ansari(University of Geneva), Evgenia Glogova(St Anna Children's Hospital), Julia Palma(Hospital Luis Calvo Mackenna), Krzysztof Kałwak(Poznan University of Medical Sciences)
Cited by 5
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation
|Blood|2004|1.6k
Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v.3.0
|Nature Protocols|2019|1.4k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738